| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Euparin primarily targets reactive oxygen species (ROS) by acting as an inhibitor. It also interacts with monoamine oxidase (MAO) in the brain, as its antidepressant effects are associated with decreased MAO activity. The compound's antiviral mechanism involves interference with the early events of the viral replication cycle, from adsorption to cells up to the first twenty minutes post-infection.
|
|---|---|
| ln Vitro |
Euparin demonstrates antiviral activity against types 1, 2, and 3 of poliovirus in Vero cells, with EC50 values of 0.47 µg/mL, 0.12 µg/mL, and 0.15 µg/mL, respectively[1].
In vitro, Euparin exhibits moderate antioxidant activity and antifungal activity against Trichophyton mentagrophytes. It shows potent antiviral activity against poliovirus types 1, 2, and 3 in Vero cells with EC50 values of 0.47 µg/mL. The compound also inhibits ROS production in cellular systems. |
| ln Vivo |
Euparin (8, 16 and 32 mg/kg) decreases behavior resembling depression in rats used in the Chronic Unpredictable Mild Stress (CUMS) model. In the brains of depressed mice, euparin at all doses has been shown to enhance monoamine neurotransmitter contents and decrease monoamine oxidase and reactive oxygen species (ROS) levels. The decrease in the expression of brain-derived neurotrophic factor (BDNF), N-methyl-D-aspartate receptor subtype 2B (NMDAR2B), and Spermidine/Spermine N1-Acetyltransferase 1 (SAT1) caused by CUMS is restored by euparine[ 2].
In vivo, Euparin demonstrates antidepressant effects in the Chronic Unpredictable Mild Stress (CUMS) mouse model. Administration of Euparin increases the contents of monoamine neurotransmitters and decreases monoamine oxidase and ROS levels in the brains of depressed mice. These findings support its potential as an antidepressant agent. |
| Enzyme Assay |
Cell-free enzymatic assays for ROS inhibition typically involve measuring the scavenging activity of Euparin against chemically generated reactive oxygen species using fluorometric or colorimetric probes such as DCFH-DA. Monoamine oxidase inhibitory activity is assessed using a spectrophotometric assay with kynuramine or tyramine as substrate, monitoring the formation of reaction products at specific wavelengths.
|
| Cell Assay |
For antiviral activity assessment, Vero cells are cultured in appropriate medium and infected with poliovirus types 1, 2, or 3. Euparin is added at various concentrations post-infection, and antiviral activity is measured by determining the EC50 values based on the inhibition of viral cytopathic effect (CPE). For antioxidant studies, cells are treated with Euparin and ROS levels are measured using fluorescent probes.
|
| Animal Protocol |
The antidepressant effect of Euparin is evaluated using the Chronic Unpredictable Mild Stress (CUMS) model in mice. Mice are subjected to various stressors over several weeks, followed by oral administration of Euparin at different doses. Behavioral tests (e.g., sucrose preference, forced swim test) are conducted, and brain tissues are collected for biochemical analysis of monoamine neurotransmitters, MAO, and ROS levels.
|
| ADME/Pharmacokinetics |
Detailed pharmacokinetic properties of Euparin have not been extensively reported in the available literature. As a small molecule with moderate lipophilicity, it is expected to be orally bioavailable and capable of crossing the blood-brain barrier to exert its antidepressant effects. Further studies are needed to characterize its absorption, distribution, metabolism, and excretion profile.
|
| Toxicity/Toxicokinetics |
Available literature does not provide comprehensive toxicological data for Euparin. However, as a natural benzofuran compound, it is generally considered to have a favorable safety profile at pharmacological doses. Standard toxicity studies including acute and sub-chronic toxicity assessments would be required for therapeutic development.
|
| References |
|
| Additional Infomation |
Euparin is a benzofuran compound and a metabolite. It has been reported in Morithamnus crassus, Senecio vernalis, and other organisms with available data.
Euparin is primarily a research compound with no reported clinical trials or regulatory approvals. Its pharmacological profile as an ROS inhibitor and antiviral agent makes it a candidate for further investigation in infectious diseases and neurological disorders. The compound's dual antioxidant and antidepressant activities suggest potential applications in conditions involving oxidative stress and mood disorders. |
| Molecular Formula |
C13H12O3
|
|---|---|
| Molecular Weight |
216.23
|
| Exact Mass |
216.079
|
| CAS # |
532-48-9
|
| PubChem CID |
119039
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.187g/cm3
|
| Boiling Point |
258.3ºC at 760mmHg
|
| Melting Point |
152-153℃
|
| Flash Point |
110ºC
|
| Index of Refraction |
1.602
|
| LogP |
3.374
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
16
|
| Complexity |
310
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(=C)C1=CC2=CC(=C(C=C2O1)O)C(=O)C
|
| InChi Key |
OPUFDNZTKHPZHM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H12O3/c1-7(2)12-5-9-4-10(8(3)14)11(15)6-13(9)16-12/h4-6,15H,1H2,2-3H3
|
| Chemical Name |
1-(6-hydroxy-2-prop-1-en-2-yl-1-benzofuran-5-yl)ethanone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.6247 mL | 23.1235 mL | 46.2471 mL | |
| 5 mM | 0.9249 mL | 4.6247 mL | 9.2494 mL | |
| 10 mM | 0.4625 mL | 2.3124 mL | 4.6247 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
